INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $377,000 | -78.3% | 10,119 | -76.3% | 0.05% | -79.8% |
| Q2 2021 | $1,739,000 | +311.1% | 42,611 | +242.0% | 0.26% | +242.7% |
| Q1 2021 | $423,000 | -50.0% | 12,459 | -53.2% | 0.08% | -56.9% |
| Q4 2020 | $846,000 | +18.8% | 26,606 | -4.1% | 0.17% | -4.4% |
| Q3 2020 | $712,000 | +33.8% | 27,737 | +33.9% | 0.18% | +2.2% |
| Q2 2020 | $532,000 | +9.7% | 20,714 | -34.4% | 0.18% | -12.3% |
| Q1 2020 | $485,000 | -48.6% | 31,554 | -56.6% | 0.20% | -8.6% |
| Q2 2019 | $944,000 | +30.9% | 72,758 | +14.9% | 0.22% | +14.4% |
| Q4 2018 | $721,000 | +79.4% | 63,304 | +231.6% | 0.19% | +115.6% |
| Q1 2018 | $402,000 | +64.8% | 19,088 | +13.4% | 0.09% | +66.7% |
| Q4 2017 | $244,000 | -16.2% | 16,826 | -8.7% | 0.05% | -16.9% |
| Q3 2017 | $291,000 | – | 18,429 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |